LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Mas
Find all relevant presentations and publications for each of our programs. From review papers to preclinical posters and clinical data presentations at medical conferences.
… programs supports ProQR’s strategic focus on Axiomer® RNAediting platform technology and continued advancement of … of its Axiomer RNAediting platform at the RNAEditingSummit in Boston. The presentation described ongoing efforts …
… Disease targeting B4GALT1 Development of Axiomer ® RNA base editing technology platform continues across multiple … Chan Medical School, Worcester July 11-13, RNAEditingSummit, Boston Financial Highlights At March 31, 2023, …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ™ RNAediting technology platform, today reported its financial and … Events In June, ProQR presented at the RNAEditingSummit in Boston, highlighting its Axiomer technology …
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators and pr
